Novel Aerosol Delivery Devices

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 4, 2015, Pages 543-551

  Singh, Supriya ^a,b   Kanbar Agha, Faisal ^a   Sharafkhaneh, Amir ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

aerosol; drug delivery; nebulizer; particle size

Indexed keywords

NANOCARRIER; AEROSOL; RESPIRATORY TRACT AGENT;

AEROSOL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DELIVERY DEVICE; DRUG TARGETING; DRY POWDER INHALER; HUMAN; LUNG FUNCTION; METERED DOSE INHALER; NANOMEDICINE; NEBULIZER; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; DEVICES; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; PARTICLE SIZE; PROCEDURES; RESPIRATION DISORDERS; RESPIRATORY CARE; TRENDS;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RESPIRATION DISORDERS; RESPIRATORY SYSTEM AGENTS; RESPIRATORY THERAPY;

EID: 84938532524     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1555612     Document Type: Article

References (50)

1. Dolovich M. B., Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet: 2011; 377 9770 1032 1045
2. Lavorini F., Fontana G. A., Usmani O. S. New inhaler devices - the good, the bad and the ugly. Respiration: 2014; 88 1 3 15
3. Zhou Q. T., Tang P., Leung S. SY, Chan J. GY, Chan H. K. Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev: 2014; 75 0 3 17
4. Hendeles L., Colice G. L., Meyer R. J. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med: 2007; 356 13 1344 1351
5. Given J., Taveras H., Iverson H., Lepore M. Prospective, open-label assessment of albuterol sulfate hydrofluoroalkane metered-dose inhaler with new integrated dose counter. Allergy Asthma Proc: 2013; 34 1 42 51
6. Guidance for Industry: Integration of Dose-Counting Mechanisms into MDI Drug Products; 2003. 1-1-2015
7. Laube B. L., Janssens H. M., de Jongh F. H., et al. European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J: 2011; 37 6 1308 1331
8. Newman S. P., Weisz A. W., Talaee N., Clarke S. W. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax: 1991; 46 10 712 716
9. Tinkelman D. Using an Autohaler®. 2012. National Jewish Health. 1-5-2015
10. National Asthma Council Australia Using Your Inhaler (Puffer) Properly Is Important When You Have Asthma or COPD (Chronic Obstructive Pulmonary Disease). 2015. 1-5-2015
11. Price D. B., Pearce L., Powell S. R., Shirley J., Sayers M. K. Handling and acceptability of the Easi-Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. Int J Clin Pract: 1999; 53 1 31 36
12. Hampson N. B., Mueller M. P. Reduction in patient timing errors using a breath-activated metered dose inhaler. Chest: 1994; 106 2 462 465
13. Julius S. M., Sherman J. M., Hendeles L. Accuracy of three electronic monitors for metered-dose inhalers. Chest: 2002; 121 3 871 876
14. Weinstein C., Staudinger H., Scott I., Amar N. J., LaForce C. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir Med: 2011; 105 7 979 988
15. Leach C. L., Davidson P. J., Hasselquist B. E., Boudreau R. J. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med: 2005; 18 4 379 385
16. Gupta R., Hindle M., Byron P. R., Cox K. A., McRae D. D. Investigation of a novel condensation aerosol generator: solute and solvent effects. Aerosol Sci Technol: 2003; 37 8 672 681
17. Barnes P. J. Triple inhalers for obstructive airways disease: will they be useful? Expert Rev Respir Med: 2011; 5 3 297 300
18. Chatterjee A., Shah M., D'Souza A. O., Bechtel B., Crater G., Dalal A. A. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res: 2012; 13 15
19. Brambilla G., Howlett D., Johnson R., Lewis D. A. Metered-Dose Inhaler and Method of Using the Same. 3-15-2012. Google Patents
20. Vehring R., Hartman M. S., Lechuga-Ballesteros D., Smith A. E., Joshi V. B., Dwivedi S. K. Compositions, Methods and Systems for Respiratory Delivery of Two or More Active Agents. 12-4-2012. Google Patents
21. Vehring R., Lechuga-Ballesteros D., Joshi V., Noga B., Dwivedi S. K. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir: 2012; 28 42 15015 15023
22. Borgstrom L., Bisgaard H., O'Callaghan C., Pedersen S. Dry-Powder Inhaler. In: Bisgaard H., O'Callaghan C., Smaldone G. C., eds. Drug Delivery to the Lungs. New York Marcel Dekker: 2002; 421 448
23. Dolovich M. B., Ahrens R. C., Hess D. R., et al. American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest: 2005; 127 1 335 371
24. Developing an Efficient Dry Powder Inhaler 3M Conix™ DPI. 2011. 1-7-2015
25. Hoppentocht M., Hagedoorn P., Frijlink H. W., de Boer A. H. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev: 2014; 75 18 31
26. Usmani O. S., Biddiscombe M. F., Barnes P. J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med: 2005; 172 12 1497 1504
27. Niven R. W., Hickey A. J. Atomization and Nebulizers. In: Hickey A. J., ed. Inhalation Aerosols. New York Informa Healthcare: 2006; 253 284
28. Daniels T., Mills N., Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev: 2013; 4 CD007639
29. Dennis J. H., Nerbrink O. New Nebulizer Technology. In: Bisgaard H., O'Callaghan C., Smaldone G. C., eds. Drug Delivery to the Lung. New York Marcel Dekker, Inc.: 2002; 303 336
30. Nikander K., Denyer J., Dodd M., et al. The Adaptive Aerosol Delivery system in a telehealth setting: patient acceptance, performance and feasibility. J Aerosol Med Pulm Drug Deliv: 2010; 23 01 S21 S27
31. Denyer J., Dyche T. The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future. J Aerosol Med Pulm Drug Deliv: 2010; 23 01 S1 S10
32. Fischer A., Stegemann J., Scheuch G., Siekmeier R. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res: 2009; 14 04 71 77
33. Rottier B. L., van Erp C. J., Sluyter T. S., Heijerman H. G., Frijlink H. W., Boer A. H. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv: 2009; 22 3 263 269
34. Lenney W., Edenborough F., Kho P., Kovarik J. M. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros: 2011; 10 1 9 14
35. Dalby R., Spallek M., Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm: 2004; 283 1-2 1 9
36. Wise R. A., Anzueto A., Cotton D., et al. TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med: 2013; 369 16 1491 1501
37. Bhavna, Ahmad F. J., Khar R. K., Sultana S., Bhatnagar A. Techniques to develop and characterize nanosized formulation for salbutamol sulfate. J Mater Sci Mater Med: 2009; 20 1 01 S71 S76
38. Suk J. S., Lai S. K., Boylan N. J., Dawson M. R., Boyle M. P., Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond): 2011; 6 2 365 375
39. Sosnik A., Carcaboso A. M., Glisoni R. J., Moretton M. A., Chiappetta D. A. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev: 2010; 62 4-5 547 559
40. Gelperina S., Kisich K., Iseman M. D., Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med: 2005; 172 12 1487 1490
41. Pison U., Welte T., Giersig M., Groneberg D. A. Nanomedicine for respiratory diseases. Eur J Pharmacol: 2006; 533 1-3 341 350
42. Pandey R., Khuller G. K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb): 2005; 85 4 227 234
43. Venegas J., Winkler T., Harris R. S. Lung physiology and aerosol deposition imaged with positron emission tomography. J Aerosol Med Pulm Drug Deliv: 2013; 26 1 1 8
44. Mentore K., Froh D. K., de Lange E. E., Brookeman J. R., Paget-Brown A. O., Altes T. A. Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. Acad Radiol: 2005; 12 11 1423 1429
45. Klein J. P., Cohen A. B., Kimberly W. T., et al. Diffusion-weighted magnetic resonance imaging of bilateral simultaneous optic nerve infarctions. Arch Neurol: 2009; 66 1 132 133
46. Plank C. Nanomagnetosols: magnetism opens up new perspectives for targeted aerosol delivery to the lung. Trends Biotechnol: 2008; 26 2 59 63
47. Dames P., Gleich B., Flemmer A., et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol: 2007; 2 8 495 499
48. Chatmongkolchart S., Schettino G. P., Dillman C., Kacmarek R. M., Hess D. R. In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. Crit Care Med: 2002; 30 11 2515 2519
49. Branconnier M. P., Hess D. R. Albuterol delivery during noninvasive ventilation. Respir Care: 2005; 50 12 1649 1653
50. Jolliet P., Tassaux D., Roeseler J., et al. Helium-oxygen versus air-oxygen noninvasive pressure support in decompensated chronic obstructive disease: A prospective, multicenter study. Crit Care Med: 2003; 31 3 878 884